GenHouse Bio

GenHouse Bio is headquartered in the Suzhou Industrial Park, a vibrant hub of talent and innovation. Dedicated to developing globally leading targeted anti-tumor drugs, the company’s core management team boasts extensive experience in corporate management, new drug R&D, and clinical development. GenHouse Bio pioneered the drug R&D philosophy of “Biology-Driven Smart Design,” and based on this concept, has built four proprietary technology platforms with sustained innovative capabilities: a structural biology platform, a new drug discovery and design platform, a druggability evaluation platform, and a translational medicine platform. Leveraging a modular and streamlined high-efficiency R&D system, the company has deeply cultivated the Ras-MAPK signaling pathway and synthetic lethality fields. It has already secured multiple clinical and pre-clinical stage products with global competitive advantages, poised to provide internationally competitive solutions for precision cancer therapy and combination treatments.